StrongNo Change
Hypoglycemic symptoms
Glargine U100 → Hypoglycemic symptoms
Glargine U100 → Hypoglycemic symptoms
Evidence profile
StrongNo ChangeSafety
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Glimepiride increases hypoglycemia risk in type 2 diabetes treatment
Key finding
Severe hypoglycemia occurred in 10 (0.8%) participants randomized to glargine.
This study evaluated the addition of glargine, glimepiride, liraglutide, or sitagliptin to metformin in type 2 diabetes. It found varying rates of hypoglycemia among the different treatments.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Extended (5–20+ y)
High bias
Last updated July 4, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Glargine U100, Glimepiride, Liraglutide, Sitagliptin
Study type
RCTs
Follow-up
Extended (5–20+ y)
Primary outcome
Severe hypoglycemia
Evidence
Moderate confidence
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the addition of glargine, glimepiride, liraglutide, or sitagliptin to metformin in type 2 diabetes. It found varying rates of hypoglycemia among the different treatments.
Clinical relevance
Understanding the risks of hypoglycemia associated with different diabetes medications is crucial for clinicians managing type 2 diabetes. This study highlights the need for careful consideration of treatment options to minimize adverse effects while effectively controlling blood sugar levels.
Keep in mind
The study did not assess long-term outcomes. Sample sizes for each intervention group may limit generalizability. Effectiveness of interventions remains unclear due to mixed results.
Published in
Journal Reference
Publication details and source links for this paper.
Elizabeth RS, Lawrence SP, Alokananda G, et al. Addition of glargine, glimepiride, liraglutide, or sitagliptin to metformin in type 2 diabetes: A randomized controlled trial. PLOS ONE. 2024;19(11):e0309907. doi:10.1371/journal.pone.0309907
Save this study and add notes to your research library.
Main Effects
Severe hypoglycemia occurred in 10 (0.8%) participants on glargine.
Severe hypoglycemia occurred in 16 (1.3%) participants on glimepiride.
Hypoglycemic symptoms were reported by 833 (68.3%) participants on glimepiride.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Glargine U100, Glimepiride, Liraglutide, and 1 more and Hypoglycemic symptoms, Severe hypoglycemia.
This study contributes evidence to
Primary intervention
Glargine U100
Primary outcomes
- Hypoglycemic symptoms
- Severe hypoglycemia
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
8
Evidence pairs
63
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
NoneNo Change
Severe hypoglycemia
Glargine U100 → Severe hypoglycemia
Glargine U100 → Severe hypoglycemia
Evidence profile
NoneNo ChangeSafety
Unlock full evidence details
StrongNo Change
Hypoglycemic symptoms
Glimepiride → Hypoglycemic symptoms
Glimepiride → Hypoglycemic symptoms
Evidence profile
StrongNo ChangeSafety
Unlock full evidence details
NoneNo Change
Severe hypoglycemia
Glimepiride → Severe hypoglycemia
Glimepiride → Severe hypoglycemia
Evidence profile
NoneNo ChangeSafety
Unlock full evidence details
StrongNo Change
Hypoglycemic symptoms
Liraglutide → Hypoglycemic symptoms
Liraglutide → Hypoglycemic symptoms
Evidence profile
StrongNo ChangeSafety
Unlock full evidence details
NoneNo Change
Severe hypoglycemia
Liraglutide → Severe hypoglycemia
Liraglutide → Severe hypoglycemia
Evidence profile
NoneNo ChangeSafety
Unlock full evidence details
StrongNo Change
Hypoglycemic symptoms
Sitagliptin → Hypoglycemic symptoms
Sitagliptin → Hypoglycemic symptoms
Evidence profile
StrongNo ChangeSafety
Unlock full evidence details
NoneNo Change
Severe hypoglycemia
Sitagliptin → Severe hypoglycemia
Sitagliptin → Severe hypoglycemia
Evidence profile
NoneNo ChangeSafety
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Glimepiride had the highest rate of hypoglycemic symptoms at 68.3%.
- Severe hypoglycemia rates were low for glargine (0.8%) and liraglutide (0.5%).
- Sitagliptin had a severe hypoglycemia rate of 0.3%.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients currently using metformin for diabetes management.
Keep in Mind
- Results may not be applicable to all populations with diabetes.
- The study focused on short-term outcomes rather than long-term effects.
- Variability in individual responses to medications may affect outcomes.
Between the Lines
- The study did not assess long-term outcomes.
- Sample sizes for each intervention group may limit generalizability.
- Effectiveness of interventions remains unclear due to mixed results.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does DPP-4 Inhibitors affect hypoglycemia?
Emerging Evidence
Current evidence does not show a clear benefit of DPP-4 Inhibitors for Hypoglycemia.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Hypoglycemic symptoms
EvidenceScore™ Emerging | EvidenceScore™ 49.1 | strong positive | ConsensusScore™ Unclear | 1 study
- 2
Severe hypoglycemia
EvidenceScore™ Limited | EvidenceScore™ 31.5 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Sulfonylureas affect hypoglycemia?
Limited Evidence
Current evidence does not show a clear benefit of Sulfonylureas for Hypoglycemia.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Hypoglycemic symptoms
EvidenceScore™ Emerging | EvidenceScore™ 49.1 | strong positive | ConsensusScore™ Unclear | 1 study
- 2
Severe hypoglycemia
EvidenceScore™ Limited | EvidenceScore™ 31.5 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect hypoglycemia?
Limited Evidence
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Hypoglycemia.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Hypoglycemic symptoms
EvidenceScore™ Emerging | EvidenceScore™ 49.1 | strong positive | ConsensusScore™ Unclear | 1 study
- 2
Severe hypoglycemia
EvidenceScore™ Limited | EvidenceScore™ 31.5 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Glargine U100 affect hypoglycemic symptoms?
Emerging Evidence
Glargine U100 appears to improve Hypoglycemic symptoms.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Hypoglycemic symptoms
EvidenceScore™ Emerging | EvidenceScore™ 49.1 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patientsLiraglutide improves glycaemic control in adults with T2DEmpagliflozin reduces body fluid volume in type 2 diabetes patientsHbA1c mediates cardiovascular benefits of GLP-1 receptor agonists
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.